Drug Profile
JBD 401
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator JINIS Biopharmaceuticals
- Class Antidementias; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dementia
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Dementia in South Korea (unspecified route) (JINIS Biopharmaceuticals pipeline, August 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Dementia in South Korea
- 12 Jun 2014 Preclinical trials in Dementia in South Korea (unspecified route) before June 2014